Sanofi India Ltd's Q3FY25 Quarter Results
- 01 Mar 2025
Result Summary
- Sanofi India Ltd reported a 1.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 26.2%.
- Its expenses for the quarter were down by 1.7% QoQ and 21.4% YoY.
- The net profit increased 11.1% QoQ and decreased 33.7% YoY.
- The earnings per share (EPS) of Sanofi India Ltd stood at 39.6 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 520.80 | 526.30 | 705.90 | -1.0% | -26.2% |
Total Expenses | 406.60 | 413.71 | 517.10 | -1.7% | -21.4% |
Profit Before Tax | 122.20 | 112.59 | 188.80 | 8.5% | -35.3% |
Tax | 30.90 | 30.40 | 51.10 | 1.6% | -39.5% |
Profit After Tax | 91.30 | 82.19 | 137.70 | 11.1% | -33.7% |
Earnings Per Share | 39.60 | 35.70 | 59.80 | 10.9% | -33.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sanofi India Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacturing, and marketing of pharmaceutical products. As a subsidiary of the global healthcare leader Sanofi S.A., the company benefits from a strong legacy of pharmaceutical expertise and innovation. Sanofi India's product portfolio includes a wide range of prescription medicines, vaccines, and consumer healthcare products. The company's commitment to providing innovative healthcare solutions is reflected in its diverse offerings that cater to various therapeutic areas. While specific recent major developments for Sanofi India Ltd are not available in this report, the company continues to operate in an environment shaped by regulatory changes, market dynamics, and advancements in medical science.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Sanofi India Ltd recorded a total income of ₹520.80 crores. This represents a decrease of 1.0% from the previous quarter (Q2FY25), where the total income was ₹526.30 crores. When compared year-over-year (YoY) to the third quarter of the fiscal year 2024 (Q3FY24), where total income was ₹705.90 crores, there is a notable decline of 26.2%. This YoY decline suggests a reduction in revenue generation capabilities or market demand fluctuations over the past year. The company's ability to maintain or increase its revenue streams forms a critical part of its financial health and performance.
Profitability
During Q3FY25, Sanofi India Ltd reported a profit before tax of ₹122.20 crores, marking an 8.5% increase from Q2FY25's ₹112.59 crores. However, this figure is a 35.3% decrease compared to Q3FY24, where the profit before tax was ₹188.80 crores. The tax expense for Q3FY25 stood at ₹30.90 crores, which is slightly higher by 1.6% from the previous quarter but lower by 39.5% when compared to the same quarter in the previous year. The profit after tax for Q3FY25 was ₹91.30 crores, reflecting an 11.1% increase from Q2FY25, but a 33.7% decrease from Q3FY24. Earnings per share (EPS) for Q3FY25 was ₹39.60, up by 10.9% from the previous quarter's ₹35.70 but down by 33.8% from Q3FY24's ₹59.80. These metrics are indicative of the company's profitability dynamics over the reporting periods.
Operating Metrics
The total expenses for Sanofi India Ltd in Q3FY25 were ₹406.60 crores, which is a reduction of 1.7% from Q2FY25, where expenses were ₹413.71 crores. Compared to Q3FY24, total expenses decreased by 21.4% from ₹517.10 crores. The reduction in expenses, both QoQ and YoY, suggests efforts in cost management or changes in operational scale. The decline in expenses in conjunction with the revenue trends provides insight into the company's operational efficiency and cost control measures within the given period. These metrics highlight the extent of the company's operational activities and financial management strategies during the quarters under review.
